OpenArc Corporate Advisory’s Travere Therapeutics TVTX Stock Holding History

OpenArc Corporate Advisory’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.13M	Buy	37,500 +6,500	+21%	+$288K	0.03%	255
2026 Q1	$921K	Hold	31,000	–	–	0.01%	334
2025 Q4	$1.18M	Buy	+31,000	New	+$1.01M	0.02%	282

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OpenArc Corporate Advisory's TVTX Position: Q2 2026 in Review

OpenArc Corporate Advisory increased its Travere Therapeutics (TVTX) stake by 21% in Q2 2026, buying an estimated $288K and bringing the position to 37,500 shares worth $2.13M. The position accounts for 0.03% of the portfolio, ranked #255.

OpenArc Corporate Advisory first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

OpenArc Corporate Advisory held 37,500 shares of Travere Therapeutics worth $2.13M as of Q2 2026.
OpenArc Corporate Advisory bought 6,500 Travere Therapeutics shares in Q2 2026, an estimated $288K.
Travere Therapeutics made up 0.03% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #255 holding.
OpenArc Corporate Advisory first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.